|
KMID : 0988920200180040355
|
|
Intestinal Research
2020 Volume.18 No. 4 p.355 ~ p.378
|
|
|
Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
|
|
Sood Ajit
Ahuja Vineet
Midha Vandana
Sinha Saroj Kant
Pai C. Ganesh
Kedia Saurabh
Mehta Varun
Bopanna Sawan
Abraham Philip
Banerjee Rupa
|
|
|
Abstract
|
|
|
|
Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD.
|
|
|
KEYWORD
|
|
|
Inflammatory bowel disease, 5-Aminosalicylic acid, Crohn disease, Colitis, ulcerative, Mesalamine
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|